Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Feng Xuan, Ph.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF, McNally P, Ramsey BW, Rayment JH, Rowe SM, Tullis E, Ahluwalia N, Chu C, Ho T, Moskowitz SM, Noel S, Tian S, Waltz D, Weinstock TG, Xuan F, Wainwright CE, McColley SA. A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele. Am J Respir Crit Care Med. 2021 Jun 15; 203(12):1522-1532. PMID: 33734030.
    Citations: 3     Fields:    
  2. Middleton PG, Mall MA, Drevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 11 07; 381(19):1809-1819. PMID: 31697873.
    Citations: 145     Fields:    Translation:HumansCTClinical Trials
  3. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 11 23; 394(10212):1940-1948. PMID: 31679946.
    Citations: 98     Fields:    Translation:HumansCTClinical Trials
  4. Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res. 2019 Apr; 5(2). PMID: 31218221.
    Citations: 16     
  5. Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1599-1611. PMID: 30334693.
    Citations: 77     Fields:    Translation:HumansCellsCTClinical Trials
  6. Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 10 25; 379(17):1612-1620. PMID: 30334692.
    Citations: 124     Fields:    Translation:HumansCTClinical Trials
  7. Kishi JY, Schaus TE, Gopalkrishnan N, Xuan F, Yin P. Programmable autonomous synthesis of single-stranded DNA. Nat Chem. 2018 02; 10(2):155-164. PMID: 29359755.
    Citations: 18     Fields:    Translation:Cells
  8. Schaus TE, Woo S, Xuan F, Chen X, Yin P. A DNA nanoscope via auto-cycling proximity recording. Nat Commun. 2017 09 25; 8(1):696. PMID: 28947733.
    Citations: 5     Fields:    Translation:Cells
  9. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016 11 03; 375(18):1738-1748. PMID: 27717303.
    Citations: 350     Fields:    Translation:HumansCTClinical Trials
  10. Kosoglou T, Statkevich P, Kumar B, Xuan F, Schiller JE, Johnson-Levonas AO, Young S, Cutler DL. The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar. J Clin Pharmacol. 2013 May; 53(5):540-9. PMID: 23426761.
    Citations: 5     Fields:    Translation:Humans
  11. Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, O'Mara E, Youngberg SP, Wagner JA, Butterton JR. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013 Mar; 56(5):718-26. PMID: 23155151.
    Citations: 22     Fields:    Translation:HumansCells
  12. Kosoglou T, Zhu Y, Xuan F, Black L, Johnson-Levonas AO, Martinho M, Statkevich P, Cutler DL. Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2012 Nov; 68(11):1509-16. PMID: 22476387.
    Citations: 3     Fields:    Translation:Humans
  13. Kosoglou T, Kraft WK, Kumar B, Statkevich P, Xuan F, Ma L, Jennings LK, Schiller JE, Langdon RB, Cutler DL. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012 Jul; 68(7):1049-56. PMID: 22315147.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  14. Kosoglou T, Reyderman L, Kasserra C, Jennings LK, Young S, Xuan F, Pei J, Maxwell SE, Schiller J, Meehan AG, Cutler DL. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012 Mar; 68(3):291-300. PMID: 21969227.
    Citations: 9     Fields:    Translation:Humans
  15. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy. 2008 Oct; 28(10):1223-32. PMID: 18823218.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Xuan's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (97)
Explore
_
Co-Authors (4)
Explore
_
Similar People (59)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.